|
 |
AzacitidineThis page contains recent news articles, when available, and an overview of Azacitidine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Researchers from France have reported a response rate of 21% and a one-year survival following treatment with Vidaza® (5-azacitidine) for patients with ... Cancer Consultants Epigenetics research takes aim at cancer, Alzheimer's, autism, other illnesses - Dec 14, 2009 Azacitidine, sold as Vidaza and used to treat bone-marrow cancer and blood disorders, became the first FDA-approved epigenetic drug in 2004. ... Washington Post Approved Vidaza Dosing Schedule May Be Better And Safer Than Alternatives (ASH ... - Dec 14, 2009 The dosing schedule of Vidaza (azacitidine) currently approved for use in Europe may be the most effective and safest treatment plan for myelodysplastic ... The MDS Beacon Beacon NewsFlashes – December 13, 2009 - Dec 13, 2009 Canada Approves Vidaza For High-Risk MDS Patients — Health Canada, the nation's drug regulator, has approved the sale and use of Vidaza (azacitidine) in ... The MDS Beacon New blood disorder treatment approved in Canada almost doubles survival rate - Dec 10, 2009 ...<< - VIDAZA is contraindicated in patients with a known hypersensitivity to azacitidine or mannitol and in patients with advanced malignant hepatic tumours. ... FOXBusiness MDS Patients Are Responsive To Sapacitabine, According To Interim Phase 2 ... - Dec 18, 2009 Dacogen (decitabine) or Vidaza (azacitidine). The participants have been divided into three groups receiving three different doses of sapacitabine. ... The MDS Beacon Cyclacel Provides Update on Meeting With FDA to Discuss Pivotal Study Design ... - Dec 15, 2009 The study has recently completed enrollment of 60 patients aged 60 or older with MDS who were previously treated with azacitidine and/or decitabine. ... CNNMoney.com (press release) EpiCept Provides Clinical and Business Update on Ceplene Program - Dec 15, 2009 Vidaza ® (azacitidine) in the treatment of patients with higher risk myelodsyplastic syndromes (MDS), a bone marrow disease that can progress to AML. ... PharmaLive.com (press release) Stofnamen toegevoegd aan beleidsregel dure geneesmiddelen - Dec 28, 2009 De stofnaam azacitidine is toegevoegd aan de beleidsregel dure geneesmiddelen. De toevoeging geldt met terugwerkende kracht tot 1 januari 2009. ... Zorgkrant ë‹›í?°ì‹ 약 MDS ì¹˜ë£Œì‹ ì•½ 'NS-17' ì‹ ì² - Dec 10, 2009 ...ë‹›í?°ì‹ 약ì?´ ëŒ€í˜•ì‹ ì•½ìœ¼ë¡œ ì„±ìž¥í• ê²ƒìœ¼ë¡œ 기대를 ëª¨ìœ¼ê³ ìžˆëŠ” 골수ì?´í˜•ì„±ì¦?후군(MDS) ì¹˜ë£Œì œ 'NS-17'(성분명:azacitidine)ì?˜ 승ì?¸ì?„ 후ìƒ?ë…¸ë?™ì„±ì—? ì‹ ì²í–ˆë‹¤ê³ 발표했다. ... 디지틀보사 L'approbation par Santé Canada de VIDAZA(R) marque une nouvelle ère de ... - Dec 10, 2009 .../CNW/ - Santé Canada a approuvé VIDAZA (azacitidine), une importante option de traitement pour les formes avancées d'un groupe de troubles sanguins graves. ... CNW Telbec (Communiqué de presse) Sunesis to Present Nonclinical Voreloxin Combination Data at AACR-EORTC-NCI ... - Nov 10, 2009 Voreloxin is Synergistic in In Vitro Combination with Cytarabine and Additive in Combination with Azacitidine, Decitabine and Clofarabine Abstract Number ... CNNMoney.com (press release) National Institute for Health and Clinical Excellence - Oct 28, 2009 The National Institute for Health and Clinical Excellence (NICE) is an independent UK organization responsible for providing guidance on the promotion of ... Prevention Action Valproic Acid May Enhance Efficacy Of Vidaza For Myelodysplastic Syndromes - Oct 21, 2009 A combination therapy of Vidaza (azacitidine) and valproic acid (Depakene) may be more effective than Vidaza alone for the treatment of myelodysplastic ... The MDS Beacon Commercial Insight: Cytotoxic Therapies - Market growth will slow due to ... - Oct 30, 2009 The launch of Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitidine; Celgene) in the 5EU and Japanese markets will contribute significantly ... PRMinds (press release) |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
